Karyopharm Therapeutics (KPTI) Preferred Stock Liabilities (2012 - 2013)
Karyopharm Therapeutics (KPTI) reported Preferred Stock Liabilities of $48.1 million for Q3 2013, up 162.92% quarter-over-quarter from $18.3 million in Q4 2012.
Karyopharm Therapeutics (KPTI) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Karyopharm Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $48.1 million in Q3 2013.
- For the quarter ending Q3 2013, Preferred Stock Liabilities changed N/A year-over-year to $48.1 million; the trailing twelve-month figure through Sep 2013 stood at $48.1 million (changed N/A YoY), and the FY2012 full-year result was $18.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2013 stood at $48.1 million, up from $18.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $48.1 million in Q3 2013, with the low at $18.3 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 48.06 Mn |
| Dec 31, 2012 | 18.28 Mn |